Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696133 | 0.89 | REN (0.53) | RENKCNH2CYP3A4 | |
| SCHEMBL696533 | 0.89 | REN (0.58) | RENKCNH2CYP3A4 | |
| SCHEMBL694310 | 0.88 | REN (0.51) | RENKCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9952555 | 0.88 | REN (0.59) | RENKCNH2CYP3A4 | |
| SCHEMBL9951986 | 0.87 | REN (0.55) | RENKCNH2CYP3A4 | |
| SCHEMBL694126 | 0.85 | REN (0.57) | RENKCNH2CYP3A4 | |
| SCHEMBL694497 | 0.85 | REN (0.56) | RENCYP3A4 | |
| SCHEMBL696074 | 0.84 | REN (0.63) | RENKCNH2CYP3A4 | |
| SCHEMBL695813 | 0.84 | REN (0.57) | RENKCNH2CYP3A4 | |
| SCHEMBL2792856 | 0.83 | REN (0.59) | RENKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | claimed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | claimed |
| WO-2010122580-A2 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | WO | claimed |
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122580-A2 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | REN 1/4885KCNH2 2700/4885CYP3A4 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.